Modality
ASO
MOA
IL-13i
Target
C5
Pathway
NF-κB
RCC
Development Pipeline
Preclinical
~Jan 2014
→ ~Apr 2015
Phase 1
~Jul 2015
→ ~Oct 2016
Phase 2
Jan 2017
→ Apr 2026
Phase 2Current
NCT03239713
1,002 pts·RCC
2025-11→2025-02·Terminated
NCT05067476
1,210 pts·RCC
2017-01→2026-04·Active
2,212 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-02-131.1y agoPh3 Readout· RCC
2026-04-091w awayPh3 Readout· RCC
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2
P2/3
Active
P2/3
Termina…
Catalysts
Ph3 Readout
2025-02-13 · 1.1y ago
RCC
Ph3 Readout
2026-04-09 · 1w away
RCC
ActiveTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03239713 | Phase 2/3 | RCC | Terminated | 1002 | eGFR |
| NCT05067476 | Phase 2/3 | RCC | Active | 1210 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxaderotide | Johnson & Johnson | NDA/BLA | PI3Kα | |
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| AMG-1919 | Amgen | Phase 2/3 | CDK2 |